Welcome to our dedicated page for Tyra Biosciences SEC filings (Ticker: TYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tyra Biosciences SEC filings document the formal disclosures of a Nasdaq-listed clinical-stage biotechnology company developing FGFR-focused precision medicines. Recent 8-K reports cover operating results, clinical-program updates for TYRA-300/dabogratinib, officer and board appointments, and capital actions under a registered at-the-market offering program.
Proxy materials describe annual meeting voting matters, board structure and corporate-governance procedures. Registration-linked disclosures and material-event reports also identify TYRA common stock, equity issuance activity, and the company’s use of SEC exhibits for press releases and other official corporate records.
Tyra Biosciences Chief Operating Officer Ashar Bhavesh received new equity awards in the form of restricted stock units and stock options. On May 5, 2026, Bhavesh was granted 15,013 RSUs, each representing a right to receive one share of common stock, and 50,295 stock options with an exercise price of $33.93 per share.
According to the vesting terms, one quarter of the RSUs vests on each of the first four anniversaries of May 5, 2026, subject to continued service. For the options, 25% of the shares vest on May 5, 2027 and the remainder vests in equal monthly installments over the following three years, with the options expiring on May 4, 2036.
Tyra Biosciences, Inc. reported that Vice President, Finance (PAO) Yuliya Rueb received equity compensation on May 5, 2026. She was granted 8,333 restricted stock units (RSUs), each representing one share of common stock, with 1/4 of the RSUs vesting on each of the first four anniversaries of May 5, 2026, subject to continued service. Following this grant, she holds 43,354 shares of common stock directly, including RSUs. She was also granted a stock option for 28,000 shares of common stock at an exercise price of $33.93 per share, expiring on May 4, 2036, with 1/48 of the option shares vesting monthly after May 5, 2026, as long as she remains in service.
Canaan-affiliated investors amend Schedule 13G/A to report beneficial ownership in Tyra Biosciences. The filing states Canaan XI L.P. and its general partner Canaan Partners XI LLC each have sole voting and dispositive power over 750,000 shares of Tyra common stock, representing 1.4% of the class. The percent is calculated using 53,867,115 shares outstanding as of February 25, 2026. The amendment also states that Canaan 2020+ Co-Investment L.P. - Series 7 and its GP no longer beneficially own any shares as of March 31, 2026.
Tyra Biosciences director Habib J. Dable received a grant of stock options covering 44,400 shares of common stock at an exercise price of $35.12 per share. The options expire on April 15, 2036 and vest monthly in 36 equal installments starting after April 16, 2026, contingent on continued service.
Tyra Biosciences, Inc. director Dable Habib J filed an initial Form 3 reporting his ownership position in the company. The filing states that no securities are beneficially owned, meaning he reports holding zero Tyra Biosciences shares at this time.
Tyra Biosciences, Inc. is asking stockholders to vote at a fully virtual 2026 Annual Meeting on May 28, 2026. Holders of Common Stock at the close of business on April 2, 2026, when 59,485,237 shares were outstanding, are entitled to vote.
Stockholders will vote on electing three Class II directors—Habib J. Dable, Susan Moran, M.D., M.S.C.E., and Robert More—for terms expiring at the 2029 annual meeting, and on ratifying Ernst & Young LLP as independent registered public accounting firm for 2026. The Board recommends voting in favor of all nominees and the auditor ratification.
Tyra Biosciences, Inc. expanded its board of directors from nine to ten members and appointed Habib J. Dable as a Class II director, with his initial term ending at the company’s 2026 annual meeting of stockholders. The board determined he qualifies as an independent director under Nasdaq rules.
In connection with his appointment, Dable received options to purchase 44,400 shares of Tyra’s common stock at the fair market value on the grant date, vesting in equal monthly installments over 36 months. He will also receive cash compensation under the company’s Non-Employee Director Compensation Program and has entered into Tyra’s standard indemnification agreement.
TYRA submitted a Form 144 notifying the proposed sale of 8,000 shares of Common stock. The filing lists shares outstanding of 53,372,098 as of 04/13/2026 and shows two prior sales by Daniel Bensen of 8,000 shares on 02/12/2026 and 8,000 shares on 03/12/2026.
FMR LLC reported beneficial ownership of 7,747,647.96 shares of Tyra Biosciences common stock, representing 14.4% of the class as of 03/31/2026. The filing shows FMR's sole voting power of 7,741,957 shares and sole dispositive power of 7,747,647.96 shares. The filing identifies Fidelity OTC Portfolio holding 2,694,729 shares (5.0%) as of the same date.